Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Azd 2281
2. Azd-2281
3. Azd221
4. Azd2281
5. Lynparza
1. 763113-22-0
2. Lynparza
3. Azd2281
4. Azd-2281
5. Ku-0059436
6. Azd 2281
7. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
8. Olaparib (azd-2281)
9. 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one
10. Ku-59436
11. Olaparib (azd2281, Ku-0059436)
12. 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2h-phthalazin-1-one
13. Az2281
14. Mfcd13185161
15. Woh1jd9ar8
16. Nsc-747856
17. C24h23fn4o3
18. Chebi:83766
19. 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2h)-one
20. 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
21. Az-2281
22. Keylynk-010 Component Olaparib
23. Ku59436
24. Olaparib Component Of Keylynk-010
25. Olaparib [inn]
26. Olaparib Cpd
27. Olaparib (azd2281; Ku-0059436)
28. Olaparib [usan:inn]
29. Unii-woh1jd9ar8
30. Olaparib (azd2281)
31. Acylpiperazine Analogue, 47
32. Olaparibum
33. Azd221
34. 4-[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2h)-one
35. Olaparib- Bio-x
36. Lynparza (tn)
37. 09l
38. 4-((3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorophenyl)methyl)phthalazin-1(2h)-one
39. 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2h)-one
40. 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2h)-one
41. Ku 59436
42. Olaparib [usan]
43. Olaparib [jan]
44. Ku0059436
45. Olaparib [mi]
46. Olaparib [vandf]
47. Olaparib - Azd2281
48. Olaparib [mart.]
49. Olaparib [who-dd]
50. Azd-2281 (olaparib)
51. Olaparib (jan/usan/inn)
52. Mls006010185
53. Schembl426568
54. Olaparib [orange Book]
55. Chembl521686
56. Gtpl7519
57. Bdbm27566
58. Dtxsid60917988
59. Ex-a002
60. Bcpp000360
61. Hms3295i09
62. Hms3426c03
63. Hms3654g13
64. Hms3746k07
65. Hms3870h03
66. Amy10295
67. Bcp01872
68. 763113-22-0, Lynparza,
69. Nsc747856
70. Nsc753686
71. S1060
72. Zinc40430143
73. Akos005145764
74. Ac-7939
75. Bcp9000363
76. Ccg-264799
77. Cs-0075
78. Db09074
79. Ex-7210
80. Nsc 747856
81. Nsc-753686
82. Sb14617
83. Ss-4573
84. Azd2281,olaparib, Ku-0059436
85. Ncgc00238451-01
86. Ncgc00238451-02
87. Ncgc00238451-08
88. Ncgc00238451-09
89. Ncgc00238451-11
90. 4-[(3-{[4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2h)-one
91. 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2h)-phthalazinone
92. Bo164169
93. Hy-10162
94. Smr004701291
95. Sy040527
96. Olaparib(azd2281,kudosku-0059436)
97. A9666
98. Bb 0260909
99. Ft-0651458
100. Ku 0059436
101. Sw218142-2
102. Ec-000.2324
103. D09730
104. J-503540
105. Q7083106
106. Brd-k02113016-001-08-9
107. Brd-k02113016-001-09-7
108. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine
109. 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one
110. (2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-
111. 1(2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-
112. 1021843-02-6
113. 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one
114. Piperazine, 1-(cyclopropylcarbonyl)-4-(5-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)-2-fluorobenzoyl)-
Molecular Weight | 434.5 g/mol |
---|---|
Molecular Formula | C24H23FN4O3 |
XLogP3 | 1.9 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 4 |
Exact Mass | 434.17541877 g/mol |
Monoisotopic Mass | 434.17541877 g/mol |
Topological Polar Surface Area | 82.1 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 790 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of: - Ovarian cancer, in which the medication is intended for [a] the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy, or [b] for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib. - Breast cancer, in which the medication is intended for use in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib.
FDA Label
* Ovarian cancer :
Lynparza is indicated as monotherapy for the:
- maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
Lynparza in combination with bevacizumab is indicated for the:
- maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5. 1).
* Breast cancer :
Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer . Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5. 1).
Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.
* Adenocarcinoma of the pancreas:
Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
* Prostate cancer :
Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum based chemotherapy.
The effect of olaparib on cardiac repolarization was assessed in 119 patients following a single dose of 300 mg and in 109 patients following multiple dosing of 300 mg twice daily. No clinically relevant effect of olaparib on QT interval was observed.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Poly(ADP-ribose) Polymerase Inhibitors
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)
L01XK01
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XK - Poly (adp-ribose) polymerase (parp) inhibitors
L01XK01 - Olaparib
Absorption
Following oral administration, the absorption of olaparib is very rapid and can reach a peak concentration ranging between 4.7 and 9.1 mcg/ml after 1-3 hours. The reported AUC of olaparib after a dose of 200 mg is of 25.8 mcg.h/L and this AUC can be increased by 26% with constant administration. The consumption of a high-fat diet with olaparib can only decrease the tmax but do not have an effect in the peak concentration.
Route of Elimination
From the administered dose, approximately 86% of the administered dose is recovered after 7 days from which 44% is found in the urine and 42% is obtained in feces.
Volume of Distribution
After administration of a dose of 100 mg/kg, the reported volume of distribution was of 40.3 L.
Clearance
The total clearance of olaparib was reported to be 4.6 L/h.
Olaparib is extensively metabolized in the liver by the action of CYP3A isoenzymes. From the administered dose, the unchanged form of olaparib accounted for 70% of the circulating dose and it was considered the major component in urine and feces. The metabolic pathway of olaparib is mainly attributable to oxidation reactions with subsequent glucuronide and sulfate conjugation. However, the over 20 metabolites found in plasma, urine, and feces represented a minor portion of the administered dose. The major circulating metabolites were represented by the mono-oxygenated form and the piperazin-3-ol form.
The reported elimination half-life ranges between 5 to 11 hours.
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2022-04-19
Pay. Date : 2022-03-31
DMF Number : 35742
Submission : 2021-03-30
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40467
Submission : 2024-09-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-05-31
Pay. Date : 2018-02-22
DMF Number : 32505
Submission : 2018-03-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31219
Submission : 2016-12-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-08-29
Pay. Date : 2022-08-10
DMF Number : 37240
Submission : 2022-08-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35831
Submission : 2021-04-17
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-10-12
Pay. Date : 2023-08-29
DMF Number : 34698
Submission : 2020-03-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-03-21
Pay. Date : 2022-12-22
DMF Number : 37779
Submission : 2023-02-09
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-11-16
Pay. Date : 2018-09-27
DMF Number : 32629
Submission : 2018-04-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-07-10
Pay. Date : 2023-06-08
DMF Number : 38395
Submission : 2023-06-18
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-034
Start Marketing Date : 2021-11-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 46708-904
Start Marketing Date : 2018-03-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54864-843
Start Marketing Date : 2017-08-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68554-0120
Start Marketing Date : 2014-12-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49187-0741
Start Marketing Date : 2018-01-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49187-0740
Start Marketing Date : 2011-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0099
Start Marketing Date : 2020-03-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17337-0319
Start Marketing Date : 2022-12-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-1464
Start Marketing Date : 2018-05-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-1400
Start Marketing Date : 2018-05-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Reliable Spanish CDMO Delivering High-Quality APIs and Intermediates with Excellence, Flexibility, and Regulatory Compliance.
About the Company : Kinsy, an independent CDMO in Spain, offers over 30 years of expertise in developing and manufacturing advanced pharmaceutical intermediates and APIs. We provide innovative route d...
About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
About the Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with...
About the Company : Cdymax (India) Pharma Private Limited was founded in 1994. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparat...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.
Lead Product(s): Pocenbrodib,Abiraterone Acetate,Olaparib
Therapeutic Area: Oncology Brand Name: FT-7051
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $365.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing May 15, 2025
Lead Product(s) : Pocenbrodib,Abiraterone Acetate,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $365.0 million
Deal Type : Series D Financing
Pathos AI Raises $365M Series D to Boost Oncology Drug Discovery via AI
Details : The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.
Product Name : FT-7051
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 15, 2025
Details:
Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of BRCA-mutated HER2-negative high-risk early breast cancer.
Lead Product(s): Olaparib
Therapeutic Area: Oncology Brand Name: Lynparza
Study Phase: Phase IIIProduct Type: Cytotoxic Drug
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2024
LYNPARZA® Shows Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
Details : Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of BRCA-mutated HER2-negative high-risk early breast cancer.
Product Name : Lynparza
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 11, 2024
Details:
Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of advanced or recurrent endometrial cancer in adults.
Lead Product(s): Olaparib,Durvalumab
Therapeutic Area: Oncology Brand Name: Lynparza
Study Phase: Approved FDFProduct Type: Cytotoxic Drug
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 27, 2024
Lead Product(s) : Olaparib,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AstraZeneca Pharma Gets nod for Sale, Distribution of Cancer Drug Lynparza
Details : Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of advanced or recurrent endometrial cancer in adults.
Product Name : Lynparza
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 27, 2024
Details:
The funds will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, to treat human cancers.
Lead Product(s): EIS-12656,Olaparib
Therapeutic Area: Oncology Brand Name: EIS-12656
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: CPRIT
Deal Size: $4.7 million Upfront Cash: Undisclosed
Deal Type: Funding November 26, 2024
Lead Product(s) : EIS-12656,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : CPRIT
Deal Size : $4.7 million
Deal Type : Funding
Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic
Details : The funds will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, to treat human cancers.
Product Name : EIS-12656
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 26, 2024
Details:
RP-3467 is a Polθ ATPase inhibitor, small molecule drug candidate, which is being evaluated in combination with olaparib for the treatment of advanced solid tumors.
Lead Product(s): RP-3467,Olaparib
Therapeutic Area: Oncology Brand Name: RP-3467
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 14, 2024
Repare Doses First Patient in Phase 1 RP-3467 Trial Targeting Polθ in Cancer
Details : RP-3467 is a Polθ ATPase inhibitor, small molecule drug candidate, which is being evaluated in combination with olaparib for the treatment of advanced solid tumors.
Product Name : RP-3467
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2024
Details:
EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.
Lead Product(s): EIS-12656,Olaparib
Therapeutic Area: Oncology Brand Name: EIS-12656
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2024
Lead Product(s) : EIS-12656,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisbach Doses First Patient in Phase 1/2 Trial for EIS-12656 in Refractory Solid Tumors
Details : EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.
Product Name : EIS-12656
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2024
Details:
Imfinzi (durvalumab) a PD-L1 inhibitor which is approved in combination with Lynparza (olaparib) for the treatment of advanced or recurrent endometrial cancer.
Lead Product(s): Durvalumab,Carboplatin,Olaparib
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 17, 2024
Lead Product(s) : Durvalumab,Carboplatin,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Imfinzi approved in the US for endometrial cancer
Details : Imfinzi (durvalumab) a PD-L1 inhibitor which is approved in combination with Lynparza (olaparib) for the treatment of advanced or recurrent endometrial cancer.
Product Name : Imfinzi
Product Type : Antibody
Upfront Cash : Inapplicable
June 17, 2024
Details:
TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.
Lead Product(s): TNG348,Olaparib
Therapeutic Area: Oncology Brand Name: TNG348
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2024
Lead Product(s) : TNG348,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medivir´s licensee, Tango Therapeutics, has Discontinued Development of its TNG348 Program
Details : TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.
Product Name : TNG348
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2024
Details:
Keytruda (pembrolizumab) is being evaluated with Lynparza (olaparib), a PARP inhibitor, for metastatic nonsquamous non-small cell lung cancer.
Lead Product(s): Pembrolizumab,Olaparib,Pemetrexed
Therapeutic Area: Oncology Brand Name: Keytruda
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: AstraZeneca
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2024
Lead Product(s) : Pembrolizumab,Olaparib,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Updates On Phase 3 KEYLYNK-006 Trial with KEYTRUDA® Plus LYNPARZA®
Details : Keytruda (pembrolizumab) is being evaluated with Lynparza (olaparib), a PARP inhibitor, for metastatic nonsquamous non-small cell lung cancer.
Product Name : Keytruda
Product Type : Antibody
Upfront Cash : Inapplicable
March 21, 2024
Details:
Imfinzi (durvalumab) with platinum-based chemotherapy followed by Lynparza (olaparib), demonstrated improved outcomes in patients with mismatch repair proficient advanced endometrial cancer.
Lead Product(s): Durvalumab,Olaparib
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2024
Lead Product(s) : Durvalumab,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lynparza and Imfinzi Demonstrated Strong Benefit Doubling Median Duration Of Response
Details : Imfinzi (durvalumab) with platinum-based chemotherapy followed by Lynparza (olaparib), demonstrated improved outcomes in patients with mismatch repair proficient advanced endometrial cancer.
Product Name : Imfinzi
Product Type : Antibody
Upfront Cash : Inapplicable
March 18, 2024
CAS Number : 57260-71-6
End Use API : Olaparib
About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...
CAS Number : 1759-53-1
End Use API : Olaparib
About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...
CAS Number : 4023-34-1
End Use API : Olaparib
About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...
1-Cyclopropyl carbonyl piperazine
CAS Number : 59878-57-8
End Use API : Olaparib
About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...
2-FLUORO-5-FORMYL BENZONITRILE
CAS Number : 218301-22-5
End Use API : Olaparib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
2-FLUORO-5-((4-OXO-3,4-DIHYDROPHTHALAZIN-1-YL) ME...
CAS Number : 763114-26-7
End Use API : Olaparib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
DIMETHYL (3-OXO-1,3-DIHYDRO-2-BENZOFURAN-1-YL) PH...
CAS Number : 61260-15-9
End Use API : Olaparib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
CAS Number : 4023-34-1
End Use API : Olaparib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
CYCLOPROPYL CARBONYL PIPERAZINE
CAS Number : 59878-57-8
End Use API : Olaparib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company : Astrazeneca
Olaparib
Drug Cost (USD) : 487,431,793
Year : 2023
Prescribers : 5974
Prescriptions : 34461
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Astrazeneca
Olaparib
Drug Cost (USD) : 460,720,287
Year : 2022
Prescribers : 6026
Prescriptions : 34404
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Astrazeneca
Olaparib
Drug Cost (USD) : 426,649,225
Year : 2021
Prescribers : 5905
Prescriptions : 32292
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Astrazeneca
Olaparib
Drug Cost (USD) : 358,856,238
Year : 2020
Prescribers : 5337
Prescriptions : 27233
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Astrazeneca
Olaparib
Drug Cost (USD) : 242,845,094
Year : 2019
Prescribers : 3908
Prescriptions : 18317
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Astrazeneca
Olaparib
Drug Cost (USD) : 119,106,528
Year : 2018
Prescribers : 2051
Prescriptions : 9055
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Astrazeneca
Olaparib
Drug Cost (USD) : 34,328,798
Year : 2017
Prescribers : 756
Prescriptions : 3194
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Astrazeneca
Olaparib
Drug Cost (USD) : 48,125,767
Year : 2016
Prescribers : 958
Prescriptions : 4660
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,776
2019 Revenue in Millions : 1,198
Growth (%) : 48
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 725
2019 Revenue in Millions : 444
Growth (%) : 63
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,348
2020 Revenue in Millions : 1,776
Growth (%) : 32
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 989
2020 Revenue in Millions : 725
Growth (%) : 36
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,116
2021 Revenue in Millions : 989
Growth (%) : 13
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 2,638
2021 Revenue in Millions : 2,348
Growth (%) : 12
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 2,811
2022 Revenue in Millions : 2,638
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,199
2022 Revenue in Millions : 1,116
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 1,311
2023 Revenue in Millions : 1,199
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 3,072
2023 Revenue in Millions : 2,811
Growth (%) : 9
Market Place
Reply
08 Nov 2024
Reply
05 Aug 2022
Reply
17 May 2022
Reply
08 Jan 2022
Reply
07 Sep 2021
Reply
03 Jul 2021
Reply
06 Jan 2021
Reply
28 Mar 2019
Reply
17 Jul 2018
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-08-12
US Patent Number : 8143241
Drug Substance Claim :
Drug Product Claim :
Application Number : 206162
Patent Use Code : U-1634
Delist Requested :
Patent Use Description : TREATMENT OF BRCA MUTA...
Patent Expiration Date : 2027-08-12
Patent Expiration Date : 2027-08-12
US Patent Number : 8071579
Drug Substance Claim :
Drug Product Claim :
Application Number : 208558
Patent Use Code : U-2482
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-08-12
Patent Expiration Date : 2029-10-07
US Patent Number : 12144810
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208558
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-10-07
Patent Expiration Date : 2029-10-07
US Patent Number : 11633396
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208558
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-10-07
Patent Expiration Date : 2027-08-12
US Patent Number : 8071579
Drug Substance Claim :
Drug Product Claim :
Application Number : 208558
Patent Use Code : U-2819
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-08-12
Patent Expiration Date : 2027-08-12
US Patent Number : 8071579
Drug Substance Claim :
Drug Product Claim :
Application Number : 208558
Patent Use Code : U-2824
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-08-12
Patent Expiration Date : 2031-08-04
US Patent Number : 8859562
Drug Substance Claim :
Drug Product Claim :
Application Number : 208558
Patent Use Code : U-2832
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-08-04
Patent Expiration Date : 2031-08-04
US Patent Number : 8859562
Drug Substance Claim :
Drug Product Claim :
Application Number : 208558
Patent Use Code : U-2819
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-08-04
Patent Expiration Date : 2027-08-12
US Patent Number : 8143241
Drug Substance Claim :
Drug Product Claim :
Application Number : 208558
Patent Use Code : U-3631
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-08-12
Patent Expiration Date : 2027-08-12
US Patent Number : 8143241
Drug Substance Claim :
Drug Product Claim :
Application Number : 208558
Patent Use Code : U-2824
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-08-12
Exclusivity Code : I-885
Exclusivity Expiration Date : 2025-03-11
Application Number : 208558
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-914
Exclusivity Expiration Date : 2026-05-31
Application Number : 208558
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-226
Exclusivity Expiration Date : 2025-12-19
Application Number : 208558
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-283
Exclusivity Expiration Date : 2026-12-27
Application Number : 208558
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-306
Exclusivity Expiration Date : 2027-05-08
Application Number : 208558
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-885
Exclusivity Expiration Date : 2025-03-11
Application Number : 208558
Product Number : 2
Exclusivity Details :
Exclusivity Code : I-914
Exclusivity Expiration Date : 2026-05-31
Application Number : 208558
Product Number : 2
Exclusivity Details :
Exclusivity Code : ODE-226
Exclusivity Expiration Date : 2025-12-19
Application Number : 208558
Product Number : 2
Exclusivity Details :
Exclusivity Code : ODE-283
Exclusivity Expiration Date : 2026-12-27
Application Number : 208558
Product Number : 2
Exclusivity Details :
Exclusivity Code : ODE-306
Exclusivity Expiration Date : 2027-05-08
Application Number : 208558
Product Number : 2
Exclusivity Details :
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
78
PharmaCompass offers a list of Olaparib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olaparib manufacturer or Olaparib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olaparib manufacturer or Olaparib supplier.
PharmaCompass also assists you with knowing the Olaparib API Price utilized in the formulation of products. Olaparib API Price is not always fixed or binding as the Olaparib Price is obtained through a variety of data sources. The Olaparib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Olaparib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olaparib, including repackagers and relabelers. The FDA regulates Olaparib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olaparib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Olaparib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Olaparib supplier is an individual or a company that provides Olaparib active pharmaceutical ingredient (API) or Olaparib finished formulations upon request. The Olaparib suppliers may include Olaparib API manufacturers, exporters, distributors and traders.
click here to find a list of Olaparib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Olaparib DMF (Drug Master File) is a document detailing the whole manufacturing process of Olaparib active pharmaceutical ingredient (API) in detail. Different forms of Olaparib DMFs exist exist since differing nations have different regulations, such as Olaparib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Olaparib DMF submitted to regulatory agencies in the US is known as a USDMF. Olaparib USDMF includes data on Olaparib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Olaparib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Olaparib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Olaparib Drug Master File in Korea (Olaparib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Olaparib. The MFDS reviews the Olaparib KDMF as part of the drug registration process and uses the information provided in the Olaparib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Olaparib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Olaparib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Olaparib suppliers with KDMF on PharmaCompass.
A Olaparib written confirmation (Olaparib WC) is an official document issued by a regulatory agency to a Olaparib manufacturer, verifying that the manufacturing facility of a Olaparib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Olaparib APIs or Olaparib finished pharmaceutical products to another nation, regulatory agencies frequently require a Olaparib WC (written confirmation) as part of the regulatory process.
click here to find a list of Olaparib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Olaparib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Olaparib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Olaparib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Olaparib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Olaparib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Olaparib suppliers with NDC on PharmaCompass.
Olaparib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Olaparib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olaparib GMP manufacturer or Olaparib GMP API supplier for your needs.
A Olaparib CoA (Certificate of Analysis) is a formal document that attests to Olaparib's compliance with Olaparib specifications and serves as a tool for batch-level quality control.
Olaparib CoA mostly includes findings from lab analyses of a specific batch. For each Olaparib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Olaparib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olaparib EP), Olaparib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olaparib USP).